BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Inclusion Criteria:

Patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis
of Urothelial cell carcinoma, Cholangiocarcinoma, Endometrial cancer, and Glioblastoma
multiforme) or hematologic malignancies and is in need of treatment because of progression
or relapse.

Patient's tumor has been evaluated and pre-identified as having a tumor with a FGFR genetic
alteration. The qualifying alteration must be assessed and reported by a CLIA-certified
laboratory.

Patient must have received at least one prior treatment for recurrent, metastatic and /or
locally advanced disease and for whom no standard therapy options are anticipated to result
in a durable remission.

Patient must have progressive and measurable disease per RECIST 1.1. or other appropriate
hematological response criteria.

Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion Criteria:

Patient has received prior treatment with BGJ398

Patients with Central Nervous System (CNS) metastasis or leptomeningeal carcinomatosis

Patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for
nitrosourea, antibodies or mitomycin-C) prior to starting study drug.

Patients with acute or chronic pancreatitis

Patients with impaired cardiac function or clinically significant cardiac diseases

History and/or current evidence of extensive tissue calcification

Use of medications that increase serum levels of phosphorus and/or calcium

Current evidence of corneal or retinal disorder/keratopathy

History and/or current evidence of renal or endocrine alterations of calcium/phosphate
homeostasis

Patients with another primary malignancy within 3 years prior to starting study treatment,
with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or
other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix